IL154841A0 - 2-amino-2-alkyl-5- heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors - Google Patents

2-amino-2-alkyl-5- heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors

Info

Publication number
IL154841A0
IL154841A0 IL15484101A IL15484101A IL154841A0 IL 154841 A0 IL154841 A0 IL 154841A0 IL 15484101 A IL15484101 A IL 15484101A IL 15484101 A IL15484101 A IL 15484101A IL 154841 A0 IL154841 A0 IL 154841A0
Authority
IL
Israel
Prior art keywords
heptenoic
amino
alkyl
acid derivatives
nitric oxide
Prior art date
Application number
IL15484101A
Other languages
English (en)
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of IL154841A0 publication Critical patent/IL154841A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/14—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/12—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines
    • C07C259/14—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxamidine groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09—Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15484101A 2000-09-15 2001-09-15 2-amino-2-alkyl-5- heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors IL154841A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23268300P 2000-09-15 2000-09-15
PCT/US2001/028673 WO2002022562A1 (en) 2000-09-15 2001-09-15 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors

Publications (1)

Publication Number Publication Date
IL154841A0 true IL154841A0 (en) 2003-10-31

Family

ID=22874118

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15484101A IL154841A0 (en) 2000-09-15 2001-09-15 2-amino-2-alkyl-5- heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
IL154841A IL154841A (en) 2000-09-15 2003-03-10 2-amino-2-alkyl-5- heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors and intermediates

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL154841A IL154841A (en) 2000-09-15 2003-03-10 2-amino-2-alkyl-5- heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors and intermediates

Country Status (26)

Country Link
US (2) US6951889B2 (de)
EP (1) EP1317421B1 (de)
JP (1) JP5009480B2 (de)
KR (1) KR100840981B1 (de)
CN (1) CN1301966C (de)
AR (1) AR030741A1 (de)
AT (1) ATE289587T1 (de)
AU (2) AU2001290883A1 (de)
BR (1) BR0113925A (de)
CA (1) CA2421504C (de)
CY (1) CY1106056T1 (de)
CZ (1) CZ2003646A3 (de)
DE (1) DE60109046T2 (de)
DK (1) DK1317421T3 (de)
EA (1) EA006244B1 (de)
ES (1) ES2238477T3 (de)
IL (2) IL154841A0 (de)
MX (1) MXPA03002207A (de)
MY (1) MY131964A (de)
NO (1) NO20031140L (de)
NZ (1) NZ524562A (de)
PL (1) PL207391B1 (de)
PT (1) PT1317421E (de)
SI (1) SI1317421T1 (de)
TW (1) TWI290130B (de)
WO (1) WO2002022562A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR032318A1 (es) * 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7312044B2 (en) 2003-03-07 2007-12-25 The Trustees Of Columbia University In The City Of New York Type 1 ryanodine receptor-based methods
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
AU2003232148A1 (en) * 2002-05-16 2003-12-02 Pharmacia Corporation A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
CN1652843A (zh) * 2002-05-16 2005-08-10 法玛西雅公司 使用选择性iNOS抑制剂治疗呼吸系统疾病和病症
KR20050059051A (ko) * 2002-08-02 2005-06-17 파마시아 코포레이션 위장 증상의 치료 및 예방 방법
ES2384969T3 (es) 2002-08-23 2012-07-16 Pharmacia Corporation Forma sólida cristalina del ácido (2S-5Z)-2-amino-7-(etanimidoilamino)-2-metilhept-5-enoico
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
CA2611105A1 (en) * 2005-06-09 2006-12-21 Mallinckrodt Inc. Method for separation and purification of naltrexone by preparative chromatography
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
AR059224A1 (es) * 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
US9895324B2 (en) * 2014-03-26 2018-02-20 University Of Kentucky Research Foundation Halogenated diarylacetylenes and methods of treating cancer
GB201512635D0 (en) 2015-07-17 2015-08-26 Ucl Business Plc Uses of therapeutic compounds
EP3398941A1 (de) * 2017-05-03 2018-11-07 AXXAM S.p.A. Heterozyklische p2x7-antagonisten
CN113861064B (zh) * 2021-10-14 2024-05-10 南京医科大学 一类神经保护剂及其药物用途
CN116693389B (zh) * 2023-06-15 2025-09-23 新元果业(山东)集团有限公司 一种合成番茄潜叶蛾性信息素(3e,8z)-3,8-十四碳二烯乙酸酯的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5132453A (en) 1991-03-22 1992-07-21 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
GB9127376D0 (en) * 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
EP0751930B1 (de) 1994-03-24 2000-01-05 G.D. SEARLE & CO. Amidino-derivative als no-synthese-inhibitoren
US5994391A (en) 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5684008A (en) 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
US5945408A (en) * 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
US5981556A (en) * 1997-07-22 1999-11-09 G.D. Searle & Co. 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors
PL198503B1 (pl) 1998-10-27 2008-06-30 Abbott Lab Związki pirydazynonowe, kompozycje farmaceutyczne je zawierające oraz ich zastosowanie

Also Published As

Publication number Publication date
DK1317421T3 (da) 2005-06-27
US6951889B2 (en) 2005-10-04
MY131964A (en) 2007-09-28
KR20030069167A (ko) 2003-08-25
WO2002022562A1 (en) 2002-03-21
EP1317421A1 (de) 2003-06-11
MXPA03002207A (es) 2003-06-24
AU2007203823A1 (en) 2007-09-06
HK1062910A1 (en) 2004-12-03
CN1301966C (zh) 2007-02-28
ES2238477T3 (es) 2005-09-01
PL207391B1 (pl) 2010-12-31
US20020132849A1 (en) 2002-09-19
TWI290130B (en) 2007-11-21
SI1317421T1 (de) 2005-08-31
PT1317421E (pt) 2005-07-29
NZ524562A (en) 2005-02-25
AU2007203823B2 (en) 2009-06-04
ATE289587T1 (de) 2005-03-15
JP2004509099A (ja) 2004-03-25
JP5009480B2 (ja) 2012-08-22
BR0113925A (pt) 2003-07-01
NO20031140L (no) 2003-05-08
DE60109046D1 (de) 2005-03-31
NO20031140D0 (no) 2003-03-12
AU2001290883A1 (en) 2002-03-26
CZ2003646A3 (cs) 2003-10-15
US20050113451A1 (en) 2005-05-26
KR100840981B1 (ko) 2008-06-24
PL361137A1 (en) 2004-09-20
IL154841A (en) 2010-12-30
EA006244B1 (ru) 2005-10-27
AR030741A1 (es) 2003-09-03
DE60109046T2 (de) 2005-08-04
EP1317421B1 (de) 2005-02-23
EA200300377A1 (ru) 2003-10-30
CN1474805A (zh) 2004-02-11
CY1106056T1 (el) 2011-04-06
CA2421504C (en) 2009-11-24
CA2421504A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
IL154842A0 (en) 2-amino-2-alkyl-4 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
PL361137A1 (en) 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
GB0031179D0 (en) Nitric oxide synthase inhibitors
AU4941501A (en) Amidino compound and salts thereof useful as nitric oxide synthase inhibitors
EP1282413A4 (de) Halogenierte 2-amino-3,4-heptensäure derivate als stickstoffmonoxid-synthase-inhibitoren
AU4430599A (en) Inhibitors of nitric oxide synthase
AU2002222252A1 (en) Nitric oxide synthase inhibitor phosphate salt
AP2000001998A0 (en) Nitric oxide synthase inhibitors
MXPA03000772A (es) Derivados de acido hexahidro-7-1h-azepin-2-il-hexanoico como inhibidores de oxido nitrico sintasa inducible.
EP1272455A4 (de) Halogenierte 2-amino-4-heptensäure-derivate als hemmstoffe der stickstoffmonoxid-synthase
PL343380A1 (en) Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors
EP1282420A4 (de) Halogenierte 2-amino-3,4-heptensäure derivate stickstoffmonoxid-synthase-inhibitoren
MXPA03002271A (es) Derivados de acido 2-amino-2-alquil-3-hexenoico y 2-amino-2-alquil-3-hexinoico utiles como inhibidores de oxido nitrico sintasa.
AU2001282746A1 (en) Novel phenylheteroazetidines, useful as nitric oxide synthase inhibitors
GB9810299D0 (en) Use of nitric oxide synthase inhibitors
AU2002355706A8 (en) Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
MXPA03002211A (es) Derivados de acido 2-amino-2-alquil-4-heptenoico y heptinoico utiles como inhibidores de la oxido nitrico sintasa.
MXPA03002272A (es) Derivados de acido 2-amino-2-alquil-3-heptenoico y 2-amino-2-alquil-3-heptenoico utiles como inhibidores de oxido nitrico sintasa.
AU2002320003A1 (en) Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
AU2002355707A1 (en) Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase
AU4446500A (en) 5,7-bicyclic amidine derivatives useful as nitric oxide synthase inhibitors
GB0031177D0 (en) Nitric oxide synthase inhibitors
AU2001282829A1 (en) Amidine derivatives which are inhibitors of nitric oxide synthase
IL130638A0 (en) Pharmaceutical compositions comprising nitric oxide synthase inhibitors
HK1056356A (en) Hexahydro-7-imino-1h-azepin-2-yl-hexanoic acid derivatives as inhibitors of inducible nitric oxide synthase